Hui-Ying Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hui-Ying Wang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Gang Li
State Grid Corporation of China, China
1 shared publication - Haiyu Yu
China Electric Power Research Institute Co..Ltd, China
1 shared publication - Huiqin Li
Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
1 shared publication - Jianhua Ma
Department of Endocrinology Nanjing First Hospital, Nanjing Medical University Nanjing China
1 shared publication - Kai Meng
China National Institution of Standardization, China
1 shared publication - Lan-Lan Jiang
Department of Endocrinology
1 shared publication
Latest Publications
- Open Access
- 27 October 2023
- Published by Association for Computing Machinery (ACM)
- p. 282-286
Research on the Optimization Model of Standard System Architecture Based on the FAST Method for Complex Business Systems
This paper analyzes the conceptual connotations of standard system and system, pointing out that standard system is characterized by system, thus a standard system architecture can be constructed by system theory. Hierarchical properties are typical features of system. In this paper, the FAST method is used to construct the standard architecture of complex business system layer by layer, and it is pointed out that the structural coordination of standard system and business system, the degree of support of standard system to the function of business system, and the coupling degree between standard sub-systems in the same level should be considered. Finally, this paper uses the FAST based on the complex business system standard body structure analysis method, taking the engineering construction standard system of State Grid Corporation of China (SGCC) as an example to carry on the case analysis. Through case analysis, it can be seen that the optimized standard architecture is more balanced and covers more comprehensive business scope.
- 27 October 2023
- Published by Association for Computing Machinery (ACM)
- p. 282-286
Open AccessResearch on the Optimization Model of Standard System Architecture Based on the FAST Method for Complex Business Systems
This paper analyzes the conceptual connotations of standard system and system, pointing out that standard system is characterized by system, thus a standard system architecture can be constructed by system theory. Hierarchical properties are typical features of system. In this paper, the FAST method is used to construct the standard architecture of complex business system layer by layer, and it is pointed out that the structural coordination of standard system and business system, the degree of support of standard system to the function of business system, and the coupling degree between standard sub-systems in the same level should be considered. Finally, this paper uses the FAST based on the complex business system standard body structure analysis method, taking the engineering construction standard system of State Grid Corporation of China (SGCC) as an example to carry on the case analysis. Through case analysis, it can be seen that the optimized standard architecture is more balanced and covers more comprehensive business scope.
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Effects of GLP‐1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52‐Week Clinical Study
Introduction. Hypoglycemic drugs affect the bone quality and the risk of fractures in patients with type 2 diabetes mellitus (T2DM). We aimed to investigate the effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and insulin on bone mineral density (BMD) in T2DM. Methods. In this single‐blinded study, a total of 65 patients with T2DM were randomly assigned into four groups for 52 weeks: the exenatide group (n = 19), dulaglutide group (n = 19), insulin glargine group (n = 10), and placebo (n = 17). General clinical data were collected, and BMD was measured by dual‐energy X‐ray absorptiometry. Results. Compared with baseline, the glycosylated hemoglobin (HbA1c) decreased significantly in the exenatide (8.11 ± 0.24% vs. 7.40 ± 0.16%, P = 0.007), dulaglutide (8.77 ± 0.37% vs. 7.06 ± 0.28%, P < 0.001), and insulin glargine (8.57 ± 0.24% vs. 7.23 ± 0.25%, P < 0.001) groups after treatment. In the exenatide group, the BMD of the total hip increased. In the dulaglutide group, only the BMD of the femoral neck decreased (P = 0.027), but the magnitude of decrease was less than that in the placebo group; the BMD of L1‐L4, femoral neck, and total hip decreased significantly (P < 0.05) in the placebo group, while in the insulin glargine group, the BMD of L2, L4, and L1‐4 increased (P < 0.05). Compared with the placebo group, the BMD of the femoral neck and total hip in the exenatide group and the insulin glargine group were increased significantly (P < 0.05); compared with the exenatide group, the BMD of L4 in the insulin glargine group was also increased (P = 0.001). Conclusions. Compared with the placebo, GLP‐1RAs demonstrated an increase of BMD at multiple sites of the body after treatment, which may not exacerbate the consequences of bone fragility. Therefore, GLP‐1RAs might be considered for patients with T2DM. This trial is registered with ClinicalTrials.gov NCT01648582.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessEffects of GLP‐1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52‐Week Clinical Study
Introduction. Hypoglycemic drugs affect the bone quality and the risk of fractures in patients with type 2 diabetes mellitus (T2DM). We aimed to investigate the effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and insulin on bone mineral density (BMD) in T2DM. Methods. In this single‐blinded study, a total of 65 patients with T2DM were randomly assigned into four groups for 52 weeks: the exenatide group (n = 19), dulaglutide group (n = 19), insulin glargine group (n = 10), and placebo (n = 17). General clinical data were collected, and BMD was measured by dual‐energy X‐ray absorptiometry. Results. Compared with baseline, the glycosylated hemoglobin (HbA1c) decreased significantly in the exenatide (8.11 ± 0.24% vs. 7.40 ± 0.16%, P = 0.007), dulaglutide (8.77 ± 0.37% vs. 7.06 ± 0.28%, P < 0.001), and insulin glargine (8.57 ± 0.24% vs. 7.23 ± 0.25%, P < 0.001) groups after treatment. In the exenatide group, the BMD of the total hip increased. In the dulaglutide group, only the BMD of the femoral neck decreased (P = 0.027), but the magnitude of decrease was less than that in the placebo group; the BMD of L1‐L4, femoral neck, and total hip decreased significantly (P < 0.05) in the placebo group, while in the insulin glargine group, the BMD of L2, L4, and L1‐4 increased (P < 0.05). Compared with the placebo group, the BMD of the femoral neck and total hip in the exenatide group and the insulin glargine group were increased significantly (P < 0.05); compared with the exenatide group, the BMD of L4 in the insulin glargine group was also increased (P = 0.001). Conclusions. Compared with the placebo, GLP‐1RAs demonstrated an increase of BMD at multiple sites of the body after treatment, which may not exacerbate the consequences of bone fragility. Therefore, GLP‐1RAs might be considered for patients with T2DM. This trial is registered with ClinicalTrials.gov NCT01648582.